6919 — Caliway Biopharmaceuticals Co Income Statement
0.000.00%
Last trade - 00:00- TWD126.10bn
- TWD121.24bn
- TWD38.04m
Annual income statement for Caliway Biopharmaceuticals Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.3 | 12.8 | 38.9 | 44.4 | 38 |
| Cost of Revenue | |||||
| Gross Profit | 9.23 | 9.61 | 27.5 | 30.8 | 26.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 243 | 332 | 552 | 762 | 745 |
| Operating Profit | -231 | -320 | -513 | -717 | -707 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -224 | -286 | -488 | -589 | -352 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -224 | -286 | -488 | -589 | -352 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -224 | -286 | -488 | -589 | -352 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -224 | -286 | -488 | -589 | -352 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.182 | -0.232 | -0.394 | -0.412 | -0.228 |
| Dividends per Share |